[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60131670D1 - Impfstoffe gegen Krebskrankheiten - Google Patents

Impfstoffe gegen Krebskrankheiten

Info

Publication number
DE60131670D1
DE60131670D1 DE60131670T DE60131670T DE60131670D1 DE 60131670 D1 DE60131670 D1 DE 60131670D1 DE 60131670 T DE60131670 T DE 60131670T DE 60131670 T DE60131670 T DE 60131670T DE 60131670 D1 DE60131670 D1 DE 60131670D1
Authority
DE
Germany
Prior art keywords
against cancer
vaccines against
cancer diseases
ascl
hash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131670T
Other languages
English (en)
Other versions
DE60131670T2 (de
Inventor
Nathalie Garcon
Catherine Marie Gerard
Jean Stephenne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025573A external-priority patent/GB0025573D0/en
Priority claimed from US09/690,921 external-priority patent/US6544518B1/en
Priority claimed from GB0025574A external-priority patent/GB0025574D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority claimed from PCT/EP2001/011984 external-priority patent/WO2002032450A2/en
Application granted granted Critical
Publication of DE60131670D1 publication Critical patent/DE60131670D1/de
Publication of DE60131670T2 publication Critical patent/DE60131670T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)
  • Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60131670T 2000-10-18 2001-10-16 Impfstoffe gegen Krebskrankheiten Expired - Lifetime DE60131670T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US690921 1996-08-01
GB0025573 2000-10-18
GB0025573A GB0025573D0 (en) 2000-10-18 2000-10-18 Vaccine
US09/690,921 US6544518B1 (en) 1999-04-19 2000-10-18 Vaccines
GB0025574A GB0025574D0 (en) 2000-10-18 2000-10-18 Vaccine
GB0025574 2000-10-18
PCT/EP2001/011984 WO2002032450A2 (en) 2000-10-18 2001-10-16 Vaccines

Publications (2)

Publication Number Publication Date
DE60131670D1 true DE60131670D1 (de) 2008-01-10
DE60131670T2 DE60131670T2 (de) 2008-10-30

Family

ID=34082077

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131670T Expired - Lifetime DE60131670T2 (de) 2000-10-18 2001-10-16 Impfstoffe gegen Krebskrankheiten

Country Status (14)

Country Link
US (1) US20050019340A1 (de)
EP (1) EP2266603B1 (de)
JP (1) JP2008285487A (de)
KR (1) KR100831139B1 (de)
AT (1) ATE534401T1 (de)
CY (3) CY1108526T1 (de)
DE (1) DE60131670T2 (de)
DK (2) DK2266603T3 (de)
ES (2) ES2392943T3 (de)
HK (3) HK1057992A1 (de)
IL (1) IL155282A (de)
PL (1) PL211151B1 (de)
PT (3) PT1326638E (de)
SI (1) SI2266603T1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
EP1608403A2 (de) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
EP1623715B1 (de) * 2004-07-13 2012-09-19 Charité - Universitätsmedizin Berlin Zusammensetzung, welche ein pharmakologisch aktives, an eine für eine Zielzelle spezifische Komponente gebundenes Mittel sowie ein Saponin enthält

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
CA1339204C (en) 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DE69428136T3 (de) 1993-03-23 2008-07-10 Smithkline Beecham Biologicals S.A. 3-0-Deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
AU3399197A (en) 1996-06-18 1998-01-07 Alza Corporation Device for enhancing transdermal agent delivery or sampling
DK0909562T3 (da) 1996-07-03 2005-08-22 Eisai Co Ltd Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
EP0930893B1 (de) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulierende oligonucleotidekonjugate
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
KR100453132B1 (ko) 1996-12-20 2004-10-15 앨자 코포레이션 경피 약제 플럭스를 향상시키기 위한 장치 및 방법
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6887660B2 (en) 1997-02-25 2005-05-03 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
JP3036686B2 (ja) 1997-02-27 2000-04-24 政夫 高橋 冠状動脈のバイパス手術に用いる血管吻合部の止血保持装置
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
HUP0001403A3 (en) 1997-04-01 2003-05-28 Corixa Corp Seattle Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP0988053A1 (de) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Gereinigte saponinen als orale adjuvantien
EP2050465B1 (de) 1997-08-29 2014-06-11 Antigenics Inc. Zusammensetzungen mit dem Adjuvans QS-21 und Polysorbat oder Cyclodextrin als Hilfsstoff
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (de) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Öl-in-Wasser Emulsionen mit Saponinen
WO1999019479A1 (en) 1997-09-26 1999-04-22 Corixa Corporation Murine model for human carcinoma
AU756828B2 (en) 1997-12-02 2003-01-23 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
NZ506086A (en) 1998-02-05 2003-01-31 Smithkline Beecham Biolog S Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins, antigens comprising derivatised thiol residues and of compositions for vaccination
JP2002511266A (ja) 1998-04-15 2002-04-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 腫瘍関連核酸及びその使用
US8574599B1 (en) * 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
EP1870466A3 (de) 1998-07-14 2008-03-19 Corixa Corporation Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Prostatakrebs
AU773204C (en) * 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
CN1133568C (zh) 1999-01-18 2004-01-07 地球制药株式会社 气溶胶扩散喷雾器
CA2361009C (en) 1999-01-29 2012-10-23 Corixa Corporation Her-2/neu fusion proteins
AU3391200A (en) 1999-03-04 2000-09-21 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
GB9905124D0 (en) * 1999-03-05 1999-04-28 Smithkline Beecham Biolog Novel compounds
EP1187629B1 (de) * 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2001002828A2 (en) * 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
KR20090085697A (ko) * 2000-02-23 2009-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
AU2010252012A1 (en) * 2009-05-27 2011-12-22 Glaxosmithkline Biologicals S.A. CASB7439 constructs

Also Published As

Publication number Publication date
HK1057992A1 (en) 2004-04-30
CY1108526T1 (el) 2014-04-09
DE60131670T2 (de) 2008-10-30
SI2266603T1 (sl) 2012-12-31
EP2266603B1 (de) 2012-09-12
JP2008285487A (ja) 2008-11-27
PT1326638E (pt) 2008-02-06
KR100831139B1 (ko) 2008-05-20
HK1147673A1 (en) 2011-08-19
DK2266603T3 (da) 2012-11-05
EP2266603A1 (de) 2010-12-29
IL155282A (en) 2010-11-30
ATE534401T1 (de) 2011-12-15
PT1889630E (pt) 2012-02-29
ES2377077T3 (es) 2012-03-22
KR20030044015A (ko) 2003-06-02
PL211151B1 (pl) 2012-04-30
CY1113735T1 (el) 2016-06-22
PT2266603E (pt) 2012-11-02
ES2392943T3 (es) 2012-12-17
US20050019340A1 (en) 2005-01-27
DK1889630T3 (da) 2012-03-05
HK1117729A1 (en) 2009-01-23
CY1112658T1 (el) 2016-02-10

Similar Documents

Publication Publication Date Title
HK1147673A1 (en) Tumour vaccines
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
DE60228758D1 (de) Immunisierung gegen chlamydia tracheomatis
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
NO20015073D0 (no) Vaksiner
NO20013749L (no) Immunologisk adjuvansforbindelse
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
ATE196737T1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
ATE463575T1 (de) Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
BR9814483A (pt) "vacina"
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
ATE387214T1 (de) Impfstoff gegen bakterielle antigene
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
AU2151902A (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
WO2002009752A3 (en) Immunological adjuvant compounds
GEP20053446B (en) Adjuvant Combination Formulations
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
DK0493575T3 (da) Vaccine af reassortant rotavirus
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: GARCON, NATHALIE, RIXENSART, BE

Inventor name: GERARD, CATHERINE MARIE GHIESLAINE, RIXENSART, BE

Inventor name: STEPHENNE, JEAN, RIXENSART, BE

8364 No opposition during term of opposition